POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSE

AUTOR(ES)

Fernandes, Guilherme Felipe dos Santos, Chin, Chung Man, Santos, Jean Leandro dos

FONTE

Quím. Nova

DATA DE PUBLICAÇÃO

2017-06

RESUMO

Tuberculosis (TB) is an infectious disease caused by mycobacteria from the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization (WHO) aims to reduce the number of TB cases worldwide in the coming years. Nevertheless, the increasing number of multidrug-resistant (MDR-TB) and extensive-drug resistance (XDR-TB) strains, and the ineffectiveness of the current treatment in latent tuberculosis are challenges to be overcome. In this review, we will demonstrate the recent advances in the tuberculosis drug discovery, focusing the research of new molecular targets in the Mycobacterium tuberculosis. Among the promising targets described herein, we highlight those, which act in different pathways in the mycobacteria, such as energy metabolism, cell wall biosynthesis, DNA synthesis, iron metabolism and transport through membranes. Furthermore, bioactive compounds discovered using phenotypic assays screening and validated through genetic approaches are also presented.

Documentos Relacionados

• Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacos
• alfa e b-glucosidases como alvos moleculares para desenvolvimento de fármacos
• O estudo da enzima deidroquinato sintase de Mycobacterium tuberculosis H37Rv como alvo para o desenvolvimento de fármacos antituberculose
• Novos fármacos para o tratamento da obesidade
• Compostos magnéticos moleculares: o desenvolvimento de novos materiais magnéticos nanoestruturados